BioSpace News Archive

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET.

- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.

Aerie Pharmaceuticals to Participate in the 20 th Annual Needham Virtual Healthcare Conference

Medcura, Inc . , a commercial-stage medical device company, announced today that it has published the results of a peer-reviewed clinical study at the University of Chicago in this month’s Cardiovascular Catheterization and Intervention

Findings reflect heightened stress on families as teens cope with isolation and embarrassment; remote schooling eases some worries but exacerbates others

Medable Inc, the leading cloud platform for patient-centered drug development, today announced the hiring of Dr. Pamela Tenaerts as Chief Scientific Officer.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham & Co. Virtual Healthcare Conference

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.